Scientific publications

What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis

Bronte G(1), Rolfo C(2), Passiglia F(1), Rizzo S(1), Gil-Bazo I(3), Fiorentino E(4), Cajozzo M(5), Van Meerbeeck JP(6), Lequaglie C(7), Santini D(8), Pauwels P(9), Russo A(1).

(1) Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy.
(2) Phase I-Early Clinical Trials Unit, Oncology Department and Multidisciplinary Oncology Center Antwerp (MOCA) Antwerp University Hospital, Edegem, Belgium.
(3) Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
(4) Department of Surgical, Oncological and Oral Sciences, Section of Surgical Oncology, University of Palermo, Palermo, Italy.
(5) Department of Surgical, Oncological and Oral Sciences, Section of Thoracic Surgery, University of Palermo, Palermo, Italy.
(6) Thoracic Oncology, Multidisciplinary Oncology Center Antwerp (MOCA) Antwerp University Hospital, Edegem, Belgium.
(7) Department of Thoracic Surgery, I.R.C.C.S.-C.R.O.B. Basilicata Regional Cancer Institute, Rionero in Vulture, Italy.
(8) Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy.
(9) Molecular Pathology Unit, Pathology Department and Multidisciplinary Oncology Center Antwerp (MOCA) Antwerp University Hospital, Edegem, Belgium.

Magazine: Critical Reviews in Oncology/Hematology

Date: Apr 11, 2015

Medical Oncology

BACKGROUND:
Randomized phase III trials showed interesting, but conflicting results, regarding the treatment of NSCLC, PS2 population. This meta-analysis aims to review all randomized trials comparing platinum-based doublets and single-agents in NSCLC PS2 patients.

MATERIALS AND METHODS:
Data from all published randomized trials, comparing efficacy and safety of platinum-based doublets to single agents in untreated NSCLC, PS2 patients, were collected. Pooled ORs were calculated for the 1-year Survival-Rate (1y-SR), Overall Response Rate (ORR), and grade 3-4 (G3-4) hematologic toxicities.

RESULTS:
Six eligible trials (741 patients) were selected. Pooled analysis showed a significant improvement in ORR (OR: 3.243; 95% CI: 1.883-5.583) and 1y-SR (OR: 1.743; 95% CI: 1.203-2.525) in favor of platinum-based doublets. G3-4 hematological toxicities were also more frequent in this group.

CONCLUSION:
This meta-analysis suggests that platinum-combination regimens are superior to singleagent both in terms of ORR and survival-rate with increase of severe hematological toxicities.

CITATION  Crit Rev Oncol Hematol. 2015 Apr 11. pii: S1040-8428(15)00066-9. doi: 10.1016/j.critrevonc.2015.03.010.

you maybe interested

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra